Page 6,659«..1020..6,6586,6596,6606,661..6,6706,680..»

Diplomat Specialty Pharmacy's 2012 Physician Satisfaction Survey Results Affirm Success of Company's Education …

Posted: Published on July 24th, 2012

FLINT, Mich., July 23, 2012 /PRNewswire/ --Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy, revealed the results of its annual Physician Satisfaction Survey today. The survey, conducted by Gartner & Associates LLC in July 2012, reaffirms Diplomat's industry leading physician satisfaction rates. Key survey findings reflect: Further, there was a 10% increase over 2011 in the number of healthcare workers who responded "very satisfied" when asked to rank their satisfaction based on the knowledge and helpfulness of Diplomat's care staff, pharmacists and nurses. Diplomat Specialty Pharmacy CEO, Phil Hagerman, says the overwhelmingly positive 2012 survey results affirm the daily efforts of the company's Education & Training center known as Diplomat University. "This type of physician-provided data reinforces the importance and value of our approach to employee training and education," notes Hagerman. "Our increases in service levels are compelling and demonstrate that we are not putting growth in front of patient services and overall care. We believe that our industry-leading Diplomat University is helping to create a more knowledgeable, helpful and compassionate team of support staff." About Diplomat Specialty Pharmacy Michigan-based Diplomat Specialty Pharmacy, founded in 1975, serves patients nationwide as the country's largest privately held Specialty Pharmacy and … Continue reading →

Posted in Pharmacy | Comments Off on Diplomat Specialty Pharmacy's 2012 Physician Satisfaction Survey Results Affirm Success of Company's Education …

LearnSomething's SpecialtyRxAdvisor™ Program Signs PANTHERx Specialty Pharmacy as Consultant

Posted: Published on July 24th, 2012

TALLAHASSEE, Fla., July 23, 2012 /PRNewswire/ --LearnSomething, distributor of the SpecialtyRxAdvisor program, has announced an exclusive partnership with PANTHERx Specialty Pharmacy. SpecialtyRxAdvisor delivers online mini-courses on specialty pharmacy drugs and services to retail pharmacy professionals. Under the agreement, PANTHERx will advise LearnSomething on the content for SpecialtyRxAdvisor programs and introduce the education programs to manufacturers who dispense specialty drugs. "SpecialtyRxAdvisor couldn't be timelier for retail pharmacies," says Dr. Gordon J. Vanscoy, associate dean and professor of pharmacy and therapeutics at the University of Pittsburgh, and chairman and CEO of PANTHERx Specialty Pharmacy. "Growth of specialty drugs is outpacing traditional medications and within a few years will account for 40 percent or more of pharmaceutical manufacturer sales. These are complex medications needing extensive management to support patient safety and adherence. It was easy for us to see how important a partnership with SpecialtyRxAdvisor can be in this growing market." Pharmacy professionals access SpecialtyRxAdvisor mini-courses using the same networks they currently use for compliance education, so integrating the program is seamless. "We have become experts at building the infrastructure and platform to provide online education to pharmacy professionals, with 85 percent penetration in retail pharmacies," says Steve Roden, president and CEO of … Continue reading →

Posted in Pharmacy | Comments Off on LearnSomething's SpecialtyRxAdvisor™ Program Signs PANTHERx Specialty Pharmacy as Consultant

Pharmacy bid wins planning appeal

Posted: Published on July 24th, 2012

23 July 2012 Last updated at 21:03 ET Plans for a pharmacy in Dumfries which had been rejected by councillors have been allowed after an appeal to the Scottish government. The local authority turned down the bid for the site on the corner of Lockerbie Road and the Laurels earlier this year. It had received a number of objections to the scheme and refused it due to road safety concerns. However, a Scottish government reporter has now ruled it can proceed with a number of conditions. The proposed scheme attracted a large number of objections - mostly concerned about traffic issues and the impact on the amenity of the area. A reporter took the view that the development of a pharmacy and its design would be in keeping with the existing character of the Lockerbie Road. He also found that evidence of any road safety issues was "neither substantive nor compelling". He said that his own site inspection had found free traffic flows were possible "most of the time" although that would rely on compliance and enforcement of double yellow lines in the area. His report concluded that the development could proceed but with a string of conditions about landscaping, … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy bid wins planning appeal

New epilepsy gene identified; possible new treatment option

Posted: Published on July 24th, 2012

ScienceDaily (July 23, 2012) New research conducted by neuroscientists from the Royal College of Surgeons in Ireland (RCSI) published in Nature Medicine has identified a new gene involved in epilepsy and could potentially provide a new treatment option for patients with epilepsy. The research focussed on a new class of gene called a 'microRNA' which controls protein production inside cells. The research looked in detail at one particular microRNA called 'microRNA-134' and found that levels of microRNA-134 are much higher in the part of the brain that causes seizures in patients with epilepsy. By using a new type of drug-like molecule called an antagomir which locks onto the 'microRNA-134' and removes it from the brain cell, the researchers found they could prevent epileptic seizures from occurring. Professor David Henshall, Department of Physiology & Medical Physics, RCSI and senior author on the paper said 'We have been looking to find what goes wrong inside brain cells to trigger epilepsy. Our research has discovered a completely new gene linked to epilepsy and it shows how we can target this gene using drug-like molecules to reduce the brain's susceptibility to seizures and the frequency in which they occur." Dr Eva Jimenez-Mateos, Department of … Continue reading →

Comments Off on New epilepsy gene identified; possible new treatment option

Reversing Paralysis: Jorge’s "Stroke" Of Luck

Posted: Published on July 24th, 2012

BACKGROUND: A stroke is like a brain attack; it occurs when a blood clot blocks an artery or a blood vessel breaks, interrupting blood flow to an area of the brain. When either happens, brain cells begin to die and brain damage occurs. Stroke is the third leading cause of death in the United States, and more than 140,000 people in the US die each year from stroke. It is the leading cause of serious, long-term disability in the United States. (Source: National Stroke Association, the Stroke Center.org) TYPES: TREATMENT: Tissue plasminogen activator (TPA), or alteplase, is a clot-buster drug that dissolves the blood clot causing the stroke. There is a narrow window of opportunity to use this drug, so the earlier that it is given, the better the result and the less potential for bleeding into the brain. Aspirin or anticoagulants like heparin are also used. Rehabilitation is also used to restore strength to the patient and get them used to their post-stroke lifestyle. (Source: MedicineNet.com) NEW TECHNOLOGY: Solitaire FR Revascularization Device is a mechanical thrombectomy device combining the ability to restore blood flow, administer medical therapy, and retrieve clot in patients experiencing acute ischemic stroke. It mechanically breaks … Continue reading →

Comments Off on Reversing Paralysis: Jorge’s "Stroke" Of Luck

The Penumbra START Trial Points to Imaging Technique That Could Predict Good Outcome for Acute Ischemic Stroke Patients

Posted: Published on July 24th, 2012

SAN DIEGO--(BUSINESS WIRE)-- The Society of NeuroInterventional Surgerys (SNIS) 9th Annual Meeting in San Diego announced today notable trial results that show scientific advancement in predicting which patients suffering from ischemic stroke will benefit from endovascular therapy--a technique that accomplishes treatment through clot-busting drugs or devices delivered through the arteries directly to the problem area in the brain. The Stroke Treatment and Revascularization Therapy (START) trial, sponsored by Penumbra, Inc., is one of the first prospective, core-lab adjudicated, multicenter studies to show a correlation between an image of the patients brain before treatment and their recovery after clot aspiration. Specifically, the study evaluated information from a brain scan about the amount of tissue affected by a stroke prior to treatment, and showed that it can be used to predict outcomes in patients undergoing endovascular care with the Penumbra System, an aspiration thrombectomy device used to remove clots from large vessels of the brain. Currently, there is no standard imaging technique to suggest which patients suffering from acute ischemic stroke should receive endovascular therapy. The CAT Scan (CT) remains the most widely used modality for stroke evaluation, but is primarily used to rule out bleeding. Changes on a non-contrast CT as … Continue reading →

Comments Off on The Penumbra START Trial Points to Imaging Technique That Could Predict Good Outcome for Acute Ischemic Stroke Patients

InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Bloomberg-TV to Discuss Spinal Cord Injury and Pain …

Posted: Published on July 24th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced that CEO Frank Reynolds is scheduled to appear on BloombergTVs Taking Stock with Pimm Fox on Tuesday, July 24th at approximately 5:30pm EDT. Taking Stock with Pimm Fox is a weekday program that airs from 5:00pm to 6:00pm EDT. InVivo Therapeutics has pioneered a new treatment using a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord. The device sparesspinal cordtissue from scarring while improving functional recovery after a traumatic SCI. In addition to the scaffold and its application for acute and chronic SCI, Reynolds will discuss new hydrogel technologies under development by InVivo. Our technology is a true platform that can be leveraged to create many neurotrauma products. InVivo is developing technologies to treat chronic injuries, as well as therapies for other nervous system conditions such as chronic pain due to nerve compression and other peripheral nerve injuries. Were currently under review at FDA for our first SCI treatment, and we look forward to receiving approval to begin those human studies in 2012, said Reynolds. About InVivo Therapeutics InVivo Therapeutics Holdings … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Bloomberg-TV to Discuss Spinal Cord Injury and Pain …

Powerful class of antioxidants may be potent Parkinson's treatment

Posted: Published on July 24th, 2012

ScienceDaily (July 23, 2012) A new and powerful class of antioxidants could one day be a potent treatment for Parkinson's disease, researchers report. A class of antioxidants called synthetic triterpenoids blocked development of Parkinson's in an animal model that develops the disease in a handful of days, said Dr. Bobby Thomas, neuroscientist at the Medical College of Georgia at Georgia Health Sciences University and corresponding author of the study in the journal Antioxidants & Redox Signaling. Thomas and his colleagues were able to block the death of dopamine-producing brain cells that occurs in Parkinson's by using the drugs to bolster Nrf2, a natural antioxidant and inflammation fighter. Stressors from head trauma to insecticide exposure to simple aging increase oxidative stress and the body responds with inflammation, part of its natural repair process. "This creates an environment in your brain that is not conducive for normal function," Thomas said. "You can see the signs of oxidative damage in the brain long before the neurons actually degenerate in Parkinson's." Nrf2, the master regulator of oxidative stress and inflammation, is -- inexplicably -- significantly decreased early in Parkinson's. In fact, Nrf2 activity declines normally with age. "In Parkinson's patients you can clearly see … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Powerful class of antioxidants may be potent Parkinson's treatment

InnerSpace Neuro Announces Launch of New, Tunneled TBI Catheter, Abstract Presentation

Posted: Published on July 24th, 2012

PHOENIX--(BUSINESS WIRE)-- InnerSpace Neuro, Inc., developer of the Hummingbird family of products used to treat Traumatic Brain Injury (TBI), today reported that an abstract featuring its Hummingbird SynergyDuo Ventricular Catheter is being presented at the Neurotrauma 2012 meeting in Phoenix, Arizona. The company also announced launch of its new Tunneled Ventricular Catheter. The abstract, authored by Dr. Howard Yonas, M.D., et al, from the University of New Mexico, showed that brain access provided by the SynergyDuo Ventricular is critical to ensuring a fixed spatial relationship between the probes with consistent placement in the brains deep frontal white matter. Over 209 procedures were part of the clinical study; 65 of those procedures used the SynergyDuo Ventricular Catheter. Parameter integration, consistencyin catheterplacement,and fixed spatial relationships of brain probes are critical elementsin caring for TBI patients, said Dr. Yonas. The Hummingbird Tunneled Ventricular Catheter, launched at the Neurotrauma meeting, is the first-ever tunneled ventricular catheter that provides dedicated ICP monitoring with continuous ventricular drainage. The companys patented AirPulse ICP technology eliminates the need for a transducer on the external ventricular drainage (EVD) mount, thereby avoiding priming, de-bubbling, breaking sterility to re-zero, and ICP leveling of fluid-filled systems. The Hummingbird Tunneled Ventricular Catheter provides … Continue reading →

Posted in Brain Injury Treatment | Comments Off on InnerSpace Neuro Announces Launch of New, Tunneled TBI Catheter, Abstract Presentation

Parkinson's, Huntington's disease research makes advances with stem cells: Discoveries

Posted: Published on July 24th, 2012

CLEVELAND, Ohio-- Imagine cooking up a new recipe for carrot cake and trying to figure out what it tastes like by feeding it to your dog. You might be able to learn something from his reactions -- Does he eat some? A lot? Does he, heaven forbid, keel over afterward? -- but you'd be pretty limited by some basic differences between you and your canine friend. Even if he could somehow tell you what he thinks, there's just no telling if cake tastes the same to a dog. This is something like the problem faced by researchers who are trying to understand and treat devastating human brain diseases like Parkinson's and Huntington's by working with mice. The mouse brain has told us a lot about the diseases, but, in the end, it's only a stand-in for working with the real thing. Now the real thing is here. Two groups of Parkinson's and Huntington's researchers working in 13 labs nationwide have used advanced stem-cell technology to make human brain cells from skin cells donated by patients with those diseases. The brain cells look and act like cells affected by the diseases, and they can be manipulated in a petri dish. Working … Continue reading →

Posted in Stem Cell Research | Comments Off on Parkinson's, Huntington's disease research makes advances with stem cells: Discoveries

Page 6,659«..1020..6,6586,6596,6606,661..6,6706,680..»